Recent Security Class Actions

Sage Therapeutics Inc. Common Stock (NASDAQ: SAGE)

22 Days left to seek lead plaintiff status.

Company Name:Sage Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: SAGE
Class Period Start:04/12/2021
Class Period End (inclusive):07/23/2024
Filing Deadline:10/28/2024

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) zuranolone was less effective in treating MDD than Defendants had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone’s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than Defendants had led investors to believe; (iv) accordingly, SAGE-718’s clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than Defendants had led investors to believe; (vi) accordingly, SAGE-324’s clinical, regulatory, and commercial prospects as a treatment for ET were overstated; and (vii) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Sage Therapeutics Inc. Common Stock (NASDAQ: SAGE) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.